ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag cancer biotech clinical trials

How Vesselon Can Improve the Entire Class of Radiopharmaceuticals
Clayton Larsen - President & CEO, Vesselon, Inc. | Nov 21, 2023 | 3 min read
Vesselon's microspheres optimize radiopharmaceuticals for targeted treatment, enhancing anti-tumor effects.
A needle drawing up fluid from an unlabeled vial.
Cancer Vaccination as a Promising New Treatment Against Tumors
Shelby Bradford, PhD | Mar 15, 2024 | 10+ min read
Vaccination has beaten back infections for more than a century. Now, it may be the next big step in battling cancer.
How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates
Clayton Larsen - President & CEO, Vesselon, Inc. | Oct 30, 2023 | 4 min read
Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.
EXCLUSIVE
Colorful pills and capsules on a calendar background
Clinical Trial Registry Errors Undermine Transparency
Catherine Offord | Aug 2, 2022 | 10 min read
A lack of comprehension among some researchers about how to use ClinicalTrials.gov may be hindering public access to trial information and holding up drug study results, an investigation by The Scientist finds.
CAR T-Cell Trials Boast Promising Results
Diana Kwon | Jun 5, 2017 | 2 min read
The results of two small clinical trials show that the immunotherapy is effective for multiple myeloma patients, at least in the near term.
natural killer cells nk cell therapy product immunotherapy clinical trial
Clinical Trial Underway for a Natural Killer Cell Therapy
Chia-Yi Hou | May 7, 2019 | 3 min read
The cells, derived from induced pluripotent stem cells, are in testing as an immunotherapy for cancer patients with solid tumors.
2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Cannabis Biotech
Daniel Cossins | Dec 1, 2014 | 8 min read
As medical marijuana businesses set up shop across the U.S., a handful of companies are taking the pharmaceutical route, guiding cannabis-derived drugs through clinical trials.

Run a Search

ADVERTISEMENT